Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.

The Journal of urology - 1 Apr 2023

Lotan Yair, Raman Jay D, Konety Badrinath, Daneshmand Siamak, Schroeck Florian, Shariat Shahrokh F, Black Peter, de Lange Michel, Asroff Scott, Goldfischer Evan, Efros Mitchell, Chong Kian Tai, Huang Eugene, Chua Hong Liang, Wu Qing Hui, Yeow Siying, Lau Weida, Yong Jin, Eng Molly

Abstract excerpt

PURPOSE: Cxbladder tests are urinary biomarker tests for detection of urothelial carcinoma. We developed enhanced Cxbladder tests that incorporate DNA analysis of 6 single nucleotide polymorphisms for the FGFR3 and TERT genes, in addition to the current 5 mRNA biomarkers and clinical risk factors. MATERIALS AND METHODS: Two multicenter, prospective studies were undertaken in: (1) U.S. patients with gross...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma in Situ
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematuria

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Risk Assessment

Share to Sensitivity and Specificity

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 36583640
DOI: 10.1097/JU.0000000000003126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.PMID 36583640Read ↗

Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary CarcinomaSemantic proximity Read ↗

Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.Semantic proximity Read ↗

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter StudySemantic proximity Read ↗

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA : a 23‐gene panel with utility for non‐invasive diagnosis and risk stratificationSemantic proximity Read ↗

Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for CystoscopySemantic proximity Read ↗

Detection of bladder cancer using urinary cell‐free DNA and cellular DNASemantic proximity Read ↗

Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.Semantic proximity Read ↗

TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.Semantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.Semantic proximity Read ↗

Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: A dual-institutional experience.Semantic proximity Read ↗

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.